Recent reports of risk factors for and survival of patients with diabetic retinopathy do not include exudative maculopathy as a separate entity.
Summary
Recent reports of risk factors for and survival of patients with diabetic retinopathy do not include exudative maculopathy as a separate entity.
We therefore studied a group of hypertensive Type II diabetic subjects with exuda tive maculopathy (n = 26) compared to a carefully matched hypertensive diabetic comparison group without retinopathy (n = 26) over seven years.
Diabetic maculopathy patients had higher mean diastolic blood pressure (101.6 ± 14 versus 94.8 ± 10 mmHg, p<0.05), serum cholesterol (6.65 ± 2.2 versus 5.9 ± 1.31 mmol/l), HDL2 subfraction levels (0.46 ± 0.23 versus 0.32 ± 0.18 mmol/l) and a higher prevalence of hype rlipidaemi a (54% versus 35%) compared to the comparison group.
After seven years, the maculopathy group showed a strikingly higher prevalence of renal failure and nephrotic syndrome (42% versus 8%, p<0.05) and of macro proteinuria (58% versus 15%, p<O.OI) compared to the comparison group. Mor tality and cardiovascular disease event rate was 12% and 38% in the maculopathy and 15% and 31 % respectively in the comparison group.
We conclude that although mortality is not significantly higher in diabetics with exudative maculopathy, proteinuria, renal failure and nephrotic syndrome may be associated features on long term follow-up. Hypertension and hypercholesterolae mia may also be risk factors in the development of diabetic maculopathy.
The classification of diabetic retinopathy used for many years contains three major groups: background, pre-proliferative and prolifera tive retinopathy. Diabetic maculopathy, which is usually considered in the background diabetic retinopathy group, is a serious cause of loss of vision in diabetic patients, and is the major cause of blindness in diabetics. ! Diabetic maculopathy is not a single path ological entity but can be classified as due to ischaemia (retinal capillary fall-out), or retinal oedema due to a breakdown of the blood retinal barrier. Macular oedema can itself be subdivided into focal oedema, which is often characterised by the presence of hard exudate rings, and diffuse oedema which typically is due to diffuse retinal leakage at the posterior pole, with absence of exudates and associated cystoid macular oedema. 2 Maculopathy occuring in diabetic patients can be difficult to classify, even with fluorescein angiography and may present a mixture of ischaemic and oedematous features. We therefore decided to examine a subgroup of diabetic maculo pathy patients which had diabetic exudative maculopathy. The advantage of choosing this group is that the exudates are readily visible on fundus examination and fundus photogra phy, so that a fluorescein angiography, a safe but nevertherless invasive procedure, would not be necessary to confirm the diagnosis.
We have compared the maculopathy patients with a carefully matched group with out retinopathy.
Patients and Methods
Patients were recruited following an ophthal mic screening of a diabetic hypertension clinic during 1982. 3 Twenty-six Type II diabetic patients with exudative maculopathy were identified, and the diagnosis confirmed in the Medical Ophthalmology clinic of the Bir mingham and Midland Eye Hospital by oph thalmoscopy, and retinal photography. The definition of maculopathy for the purposes of this study was the presence of exudates within two disc diameters of the fovea. None of these patients had proliferative retinal changes. Twenty-six Type II diabetic pat�ents were also identified who had no evidence of diabetic ret inopathy on direct ophthalmoscopy but who were closely matched for age, sex, duration and treatment of diabetes mellitus.
All patients had routine physical examin ation including blood pressure measurement using a random zero sphygmomanometer. Hypertension was defined according to the WHO criteria4 and appropriate cuff correc tion for obesity made. s Urine was tested with albustix on two differing occasions. Blood samples were taken following an overnight fast (12 hours) for urea and electrolytes, crea tinine, fasting lipids and lipoproteins. Hyper lipidaemia was defined as fasting serum cholesterol >6. 5 mmol/l or triglyceride >2. 1 mmol/1. 6 High density lipoprotein chol esterol (HDL) was measured following pre cipitation of very low density lipoprotein (VLDL) by the heparin manganese method. 7 HDL 2 subfraction was assayed by the low molecular weight dextran sulphate precipita tion technique. 8 Following a seven year follow-up, patients were assessed with regard to outcome. Deaths were identified by notes and certificates obtained to ascertain cause of death. Other events induding stroke, myocardial infarc tion, peripheral vascular disease, cardiac fail ure, development of macroproteinuria (on albustix ;:: + consistently), renal failure (crea tinine ;:: 130 /-lmoUI) and frank nephrotic syn· drome (peripheral oedema, low serum albumin and proteinuria >1 gm/day) were recorded.
Statistics and analysis were performed on an IBM compatible computerised system using the Oxstat package. Unpaired t-test was used for cross-sectional data and the chi. squared test for follow·up data.
Results
The initial clinical details of the patients stud ied are shown in Table I . The two groups of hypertensive Type II diabetics were well matched for clinical parameters including type of diabetic treatment and duration of both diabetes and hypertension. However, it was noted that twice as many Type II diabetiC! hypertensive subjects with maculopathy were on thiazide diuretic therapy for hypertension.
There was a trend towards a higher preva lence of hyperlipidaemia with a higher meat! serum cholesterol in the maculopathy group. Hypercholesterolaemia was the predominant form of hyperlipidaemia in both groups (Mac ulopathy 10 of 14 patients: and comparison group, six of nine patients). In those patients with confirmed hyperlipidaemia thyroid and renal function (creatinine <120 /-lmolll) were normal. The initial prevalence of proteinuria, current smokers (15% versus 12%) and alcohol intake (patients >2 units/day, 19% versus 15%) were similar in the two groups. Mean blood pressure and biochemical values of the two groups are shown in Table II . Dias. tolic blood pressure was significantly higher ill those with maculopathy (p<0. 05). There wa, a trend to higher mean serum HDL and total cholesterol, with significantly higher subfrac tion HDL 2 values (p<0. 03), but mean trio glyceride levels were similar.
During the seven year follow-up period, anti-hypertensive therapy remained unchanged. Three patients in the macula pathy group were treated with bezafibrate fOJ marked hypercholesterolaemia (fasting choJ- esterol values initially: 9, 8. 8, and 15 mmol/l) whereas all other identified hyperlipidaemic subjects in both groups were treated with low fat dietary advice. The results of assessment of patients after seven year follow-up with regard to outcome are shown in Table III . Sig nificantly more patients developed macro albuminuria, nephrotic syndrome and chronic renal failure in diabetic patients with mac ulopathy compared to the comparison group. Overall mortality was similar in the two groups, and cardiovascular disease end points were comparable, showing no excess of myo cardial infarction in those with maculopathy.
Discussion
The major findings in this small study suggest that there may be an excess of hyperlipid aemia and poorly controlled hypertension associated with maculopathy in Type II dia betic hypertensive subjects. The major development on long follow-up of maculo pathy appears to be the renal complications of diabetes, whereas cardiovascular disease events show no major difference from those hypertensive Type II diabetics without mac ulopathy. The association of increased thia zide diuretic usage in patients with maculopathy is interesting owing to the adverse effects on blood glucose control and lipid levels that these agents are known to have. 9 It appears from other studies of the micro circulation of the retina,1O that hyperlipidae mia predisposes to venous and arteriolar occlusion, whereas HDL-cholesterol levels are not related. This study supports this find ing with increased rather than lower values of HDL and HDL 2 subfraction cholesterol values in diabetic exudative maculopathy patients.
This study has limitations and caution must be exercised in over-interpretation. The initial study groups were small in number and the follow-up of these patients was performed in routine hospital diabetic clinic, allowing variations in exact management. These fac tors may minimise major initial differences between the groups and variation in individ ual patient management may have an influ ence on outcome. The exact degree of control of hypertension, hyperlipidaemia and diabetes related to outcome is not addressed by this study owing to paucity of standardised data.
However this report does suggest that hyperlipidaemia and control of hypertension might be related to the development of dia- (1) 4% (1) 12% (3) 4% (1) 12% (3) 12% (3) 8% (2) 4% (1) 8% (2) 12% (3) 38.5% (10) 31 % (8)
betic maculopathy. Hypertension is well described as a risk factor for development of macro-and microvascular complications of diabetes. 11,1 2 One recent report has high lighted the adverse association of increased mortality and the ocular complications of diabetes, 13 These include moderate to severe non-proliferative and proliferative retino pathy, cataract, and glaucoma (both neovas cular and other causes) in both Type I and Type II diabetic patients. No data is included specifically with regard to exudative maculo pathy. 13 Further suggestive support for a link between hyperlipidaemia and exudative mac ulopathy is added by the reduction of exu dates associated with clofibrate therapy,14 and one previous report linking retinal exudation and hypercholesterolaemia, 15 Further studies are needed to address these issues. As maculopathy is still the major cause of blindness in diabetic subjects, it is all the more urgent to identify the risk factors for this disorder, which might lead to benefit from medical treatment as well as laser therapy. Indeed this hypothesis is being explored with regard to the effect of lipid lowering therapy in relation to the development of microalbu minuria in diabetic subjects. Animal experi ments have suggested there may be benefit using the HMG eoA reductase inhibitor drugs to lower LDL-cholesterol levels. 16 We conclude from this small study that hypertension and hyperlipidaemia may hi associated in a diabetic patient with tilt development of exudative mac4lopathy. Fol low-up data suggests an association of exuda tive maculopathy with the renal complications of diabetes.
